Dr. Tina Q. Tan discusses the COVID-19 vaccine in kids 5-11 years

Video

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the approval of the COVID-19 vaccine for children aged 5 to 11 years and conversations with parents.

The authorization of the Pfizer/BioNTech COVID-19 vaccine in children aged 5 to 11 years has been met with positive reactions from pediatricians and many parents. As the rollout to the age group starts, allaying safety fears and knowing who to turn to for the vaccine are key. The editor-in-chief of Contemporary Pediatrics, Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sat down with the editorial team to answer some common questions.

Recent Videos
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Tina Tan, MD
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age | Image credit: Contemporary Pediatrics

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

Joshua Fitch, Senior Editor
June 12th 2025
Article

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital

Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention

Octavio Ramilo, MD
June 10th 2025
Article

Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Renewed focus into Staphylococcus aureus risk in infants, with Aaron Milstone, MD

Renewed focus into Staphylococcus aureus risk in infants, with Aaron Milstone, MD

Aaron Milstone, MD, MHS
June 6th 2025
Article

Aaron Milstone, MD, emphasizes the need for better recognition and prevention of Staphylococcus aureus infections in neonatal intensive care units.

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels | Image Credit: © Monir - © Monir - stock.adobe.com.

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels

Joshua Fitch, Senior Editor
June 5th 2025
Article

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

© 2025 MJH Life Sciences

All rights reserved.